Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Mario E Lacouture, Milan J Anadkat, René-Jean Bensadoun, Jane Bryce, Alexandre Chan, Joel B Epstein, Beth Eaby-Sandy, Barbara A Murphy, MASCC Skin Toxicity Study Group, Andrei Barasch, Camilla Beder, Christine B Boers-Doets, Tracey Doherty, Judith E Raber, Dion Forstner, Seppo Langer, Judith Lees, Dan Mellor, Mario E Lacouture, Milan J Anadkat, René-Jean Bensadoun, Jane Bryce, Alexandre Chan, Joel B Epstein, Beth Eaby-Sandy, Barbara A Murphy, MASCC Skin Toxicity Study Group, Andrei Barasch, Camilla Beder, Christine B Boers-Doets, Tracey Doherty, Judith E Raber, Dion Forstner, Seppo Langer, Judith Lees, Dan Mellor

Abstract

Background: Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.

Methods: A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.

Results: Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.

Conclusion: Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

Figures

Fig. 1
Fig. 1
a Mild papulopustular (acneiform) rash, b and c papulopustular (acneiform) rash, d and e radiation dermatitis, f and g mucositis, h fingertip fissure, and i paronychia

References

    1. Balagula Y, Garbe C, Myskowski P, Hauschild A, Rapoport B, Boers-Doets CB, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011;50:129–146.
    1. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007;72(3–4):152–159.
    1. Somerfield M, Padberg J, Pfister D, et al. ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Classic Papers Curr Comments. 2000;4:881–886.
    1. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–812.
    1. Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie. 2010;33(3):94–98.
    1. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL (2010) Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer (in press)
    1. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4) Oncologist. 2010;15(9):1016–1022.
    1. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB) Cancer. 2008;113(4):847–853.
    1. Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol. 2009;61(4):614–620.
    1. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–1357.
    1. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34):5390–5396.
    1. Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab—a report of 29 patients. Eur J Dermatol. 2010;20(1):82–84.
    1. Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y (2006) Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol ASCO Annual Meeting Proceedings part I, vol. 24, no. 18S (June 20 Supplement)
    1. Radovics N, Kornek G, Thalhammer F, Weihsengruber F, Pietrzak C, Resch G, Petzer AL, Hauser I, Wogritsch C, Greil R (2010) Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 28:15S (May 20 Supplement)
    1. Bidoli P, Cortinovis DL, Colombo I, Crippa A, Cicchiello F, Villa F, Cazzaniga ME, Altomare G. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(10):1662–1663.
    1. Vezzoli P, Marzano AV, Onida F, Alessi E, Galassi B, Tomirotti M, Berti E. Cetuximab-induced acneiform eruption and the response to isotretinoin. Acta Derm Venereol. 2008;88(1):84–86.
    1. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol. 2005;153(4):849–851.
    1. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767–774.
    1. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385.
    1. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541–553.
    1. Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc. 2009;7(S1):s5–s21.
    1. Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. JEADV. 2010;24:453–459.
    1. Hoffmann R. A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% creamin the treatment of unwanted facial hair in women using TrichoScan. Eur J Dermatol. 2008;18(1):65–70.
    1. Jackson J, Caro JJ, Caro G, Garfield F, Huber F, Zhou W, Lin CS, Shander D, Schrode K, Eflornithine HCl Study Group The effect of eflornithine 13.9% cream on the bother and discomfort due tohirsutism. Int J Dermatol. 2007;46(9):976–981.
    1. Amin SP, Goldberg DJ. Clinical comparison of four hair removal lasers and light sources. J Cosmet Laser Ther. 2006;8(2):65–68.
    1. Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol. 2007;57(1):54–59.
    1. Smith SR, Piacquadio DJ, Beger B, Littler C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg. 2006;32(10):1237–1243.
    1. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at
    1. Campbell IR, Illingworth MH. Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial. Clin Oncol (R Coll Radiol) 1992;4:78–82.
    1. Roy I, Fortin A, Larochelle M. The impact of skin washing with water and soap during breast irradiation: a randomized study. Radiother Oncol. 2001;58:333–339.
    1. Salvo N, Barnes E, Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, Angelis C. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol. 2010;17(4):94–112.
    1. Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Stoffel TJ, Haselow RE, Schaefer PL, Bearden JD, 3rd, Atherton PJ, Loprinzi CL, Martenson JA. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys. 2010;79:1460–1466.
    1. Elliott EA, Wright JR, Swann RS, et al. Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol. 2006;24:2092–2097.
    1. Aygenc E, Celikkanat S, Kaymakci M, et al. Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngol Head Neck Surg. 2004;130:351–356.
    1. Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int J Radiat Oncol Biol Phys. 2006;65:745–750.
    1. Segaert S, Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–1433.
    1. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005;3:599–606.
    1. Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006;55:429–437.
    1. Racca P, Fanchini L, Caliendo V, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an Oncologic/Dermatologic Cooperation. Clin Colorectal Cancer. 2008;7:48–54.
    1. Monroe EW, Bernstein DI, Fox RW, et al. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung. 1992;42:1119–1121.
    1. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992;14(1):17–21.
    1. Porzio G, Aielli F, Verna L, Porto C, Tudini M, Cannita K, Ficorella C. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage. 2006;32:397–398.
    1. Goutos I, Eldardiri M, Khan AA, Dziewulski P, Richardson PM. Comparative evaluation of antipruritic protocols in acute burns. The emerging value of gabapentin in the treatment of burns pruritus. J Burn Care Res. 2010;31(1):57–63.
    1. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19(12):3137–3139.
    1. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363:397–398.
    1. Bromm B, Scharein E, Darsow U, Ring J. Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett. 1995;187:157–160.
    1. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol. 1995;131(12):1403–1408.
    1. Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A. Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol. 2007;26(3):249–255.
    1. Pour-Reza-Gholi F, Nasrollahi A, Firouzan A, Nasli Esfahani E, Farrokhi F. Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iran J Kidney Dis. 2007;1(1):34–37.
    1. Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol. 2010;9(8):992–997.
    1. Yaffe SJ, et al. Antihistamine in topical preparations. Pediatrics. 1973;51:299–301.
    1. Khuntia D, Harris J, Bentzen SM, et al. Increased oral mucositis after IMRT versus non-IMRT when combined with cetuximab and cisplatin or docetaxel for head and neck cancer: preliminary results of RTOG 0234. Int J Radiat Oncol Biol Phys. 2008;72(1):S33.
    1. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003;21(1):99–101.
    1. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2004;22(13):2610–2616.
    1. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201–1208.
    1. Reynolds NA, Wagstaff AJ. Cetuximab—in the treatment of metastatic colorectal cancer. Drugs. 2004;64(1):109–118.
    1. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177.
    1. Belani CP, Schreeder MT, Steis RG, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008;113(9):2512–2517.
    1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med. 2008;359(11):1116–1127.
    1. Thomas M. Cetuximab: adverse event profile and recommendations for toxicitmanagement. Clin J Oncol Nurs. 2005;9(3):332–338.
    1. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology. 2006;20(5 Suppl 2):5–13.
    1. Keefe DM, Schubert MM, Elting LS, St S, Epstein JB, Raber-Drulacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucostis. Cancer. 2007;109(5):820–831.
    1. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(9):2026–2046.
    1. Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: part II: clinical perspectives and management. J Dent Res. 2007;86(6):506–518.
    1. Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E. Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec Care Dent. 2008;28(1):27–31.
    1. Gorsky M, Epstein JB, Sl R, Elishoov H, Yarom N. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J. 2007;13(2):1.
    1. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer. 2009;10(2):106–111.
    1. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317–326.
    1. Ricciardi S, Tomao S, Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009;10(1):28–35.
    1. Saif MW, Kaley K, Lamb L, Pecerillo J, Hotchkiss S, Steven L, Brennan M, Penney R, Gillespie C, Shaib W. Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. JOP. 2010;11(2):176–182.
    1. Gutzmer R, Werfel T, Kapp A, Elsner J. Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt. 2006;57(6):509–513.
    1. Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, Pawel J, Temel J, Siena S, Soulières D, Saltz L, Leyden J. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10(5):345–356.
    1. Wollenberg A, Kroth J, Hauschild A, Dirschka T. Cutaneous side effects of EGFR inhibitors—appearance and management. Dtsch Med Wochenschr. 2010;135(4):149–154.
    1. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 2005;23(1):165–174.
    1. Jennings MB, Alfieri D, Ward K, Lesczczynski C. Comparison of salicylic acid and urea versus ammonium lactate for the treatment of foot xerosis. A randomized, double-blind, clinical study. J Am Podiatr Med Assoc. 1998;88(7):332–336.
    1. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144(6):1169–1176.
    1. Becker A, Wijk A, Smit EF, Postmus PE. Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1477–1480.
    1. OSI Pharmaceuticals (2005) Tarceva package insert
    1. ImClone Systems (2006) Erbitux package insert
    1. Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161(3):515–521.
    1. Hong SH, Wong CW, Privalsky ML. Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor. Mol Endocrinol. 1998;12:1161–1171.
    1. Baran R. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol. 1986;11:148–152.
    1. Bouscarat F, Bouchard C, Bouhour D. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med. 1998;338:1776–1777.
    1. Sassone LM, Fidel RA, Murad CF, Fidel SR, Hirata R., Jr Antimicrobial activity of sodium hypochlorite and chlorhexidine by two different tests. Aust Endod J. 2008;34(1):19–24.
    1. Eames T, Grabein B, Kroth J, Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol. 2010;24(8):958–960.
    1. Floersheim GL. Treatment of brittle fingernails with biotin. Z Hautkr. 1989;64(1):41–48.
    1. Tosti A, Piraccini BM, Ghetti E, Colombo MD. Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol. 2002;47(1):73–76.
    1. Wollina U. Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid. J Eur Acad Dermatol Venereol. 2001;15(1):82–84.
    1. Rao A, Bunker C. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol. 2010;163(1):208.
    1. Rigopoulos D, Gregoriou S, Belyayeva E, Larios G, Ontochristopoulos G, Katsambas A. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol. 2009;160(4):858–860.
    1. Daniel CR, 3rd, Daniel MP, Daniel CM, Sullivan S, Ellis G. Chronic paronychia and onycholysis: a thirteen-year experience. Cutis. 1996;58:397–401.
    1. Rosenbaum D, Merenstein D, Meyer F. Topical steroids more effective than antifungals for chronic paronychia. J Fam Pract. 2002;51:824.
    1. Roberts DT, Richardson MD, Dwyer PK, Donegan R. Terbinafine in chronic paronychia and candida onychomycosis. J Derm Treat. 1992;S1:39–42.
    1. Rutala WA, Weber DJ. Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin Microbiol Rev. 1997;10(4):597–610.
    1. Shu KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006;154(1):191–192.
    1. Wilhelmi BJ, Calianos TA, II, Appelt EA, Ortiz ME, Heggers JP, Phillips LG. Modified Dakin’s solution for cutaneous vibrio infections. Ann Plast Surg. 1999;43(4):386–389.
    1. Rutala WA, Cole EC, Thomann CA, Weber DJ. Stability and bactericidal activity of chlorine solutions. Infect Control Hosp Epidemiol. 1998;19(5):323–327.
    1. Quitkin HM, Rosenwasser MP, Strauch RJ. The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand. J Hand Surg Am. 2003;28(3):435–438.
    1. Ghodsi SZ, Raziei M, Taheri A, Karami M, Mansoori P, Farnaghi F. Comparison of cryotherapy and curettage for the treatment of pyogenic granuloma: a randomized trial. Br J Dermatol. 2006;154(4):671–675.
    1. Saltz L, Rubin MS, Hochster H, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor. Clin Cancer Res. 2001;7:3766s.
    1. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25(26):4096–4103.
    1. Lièvre A, Bachet JB, Boige V, Cayre A, Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374–379.
    1. Lenz HJ, Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluropyrimidines. J Clin Oncol. 2006;24(30):4814–4921.
    1. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77–85.
    1. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA. Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;29(7):760–766.
    1. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006;24(12):1807–1813.
    1. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Phase II trial of gefitinib 250 mg po daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(23):8418–8424.
    1. Meropol NJ, Berlin J, Hecht JR, et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2003;22:256.
    1. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3238–3247.
    1. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol. 2004;22(5):785–794.
    1. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18:509–522.
    1. MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT). Available at
    1. NCI Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Available at
    1. Chan A, Tan EH (2010) How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer (in press)

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi